# A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

> **NCT00112281** · PHASE3 · TERMINATED · sponsor: **Arginox Pharmaceuticals** · enrollment: 658 (—)

## Conditions studied

- Shock, Cardiogenic

## Interventions

- **DRUG:** Tilarginine Acetate Injection intravenous infusion

## Key facts

- **NCT ID:** NCT00112281
- **Lead sponsor:** Arginox Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 658 (—)
- **Last updated:** 2006-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112281, "A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00112281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*